Abstract
Alzheimers disease (AD) is the most prevalent neurodegenerative disease in the growing population of elderly people. A characteristic of AD is the accumulation of plaques in the brain of AD patients, and theses plaques mainly consist of aggregates of amyloid β-peptide (Aβ). All converging lines of evidence suggest that progressive accumulation of the Aβ plays a central role in the genesis of Alzheimers disease and it was long understood that Aβ had to be assembled into extracellular amyloid fibrils to exert its cytotoxic effects. This process could be modulated by molecular chaperones which inhibit or accelerate the amyloid formation. The enzyme Acetylcholinesterase (AChE) induces Aβ fibrils formation, forming a stable complex highly neurotoxic. On the other hand, laminin inhibit the Aβ fibrils formation and depolymerizate Aβ fibrils also. Over the past decade, data have emerged from the use of several sources of Aβ (synthetic, cell culture, transgenic mice and human brain) to suggest that intermediate species called Aβ oligomers are also injurious. Accumulating evidence suggests that soluble forms of Aβ are indeed the proximate effectors of synapse loss and neuronal injury. On the other hand, the member of the Wnt signaling pathway, β-catenin was markedly reduced in AD patients carrying autosomal dominant PS-1. Also, neurons incubated with Aβ revealed a significant dose-dependent decrease in the levels of cytosolic β-catenin an effect which was reversed in cells co-incubated with increasing concentrations of lithium, an activator of Wnt signaling pathway. Wnt signaling blocks the behavioural impairments induced by hippocampal injection of Aβ, therefore the activation of Wnt signaling protects agains the Aβ neurotoxicity. Here we review recent progress about Aβ structure and function, from the formation of amyloid fibrils and some molecular chaperones which modulate the amyloidogenesic process to synaptic damage induce by Aβ oligomers.
Keywords: Alzheimer's disease, senile plaque, amyloid β-peptide, neurodegeneration, synaptic toxicity, amyloid oligomers, acetylcholinesterase, Wnt-signaling pathway
Current Alzheimer Research
Title: Structure-Function Implications in Alzheimers Disease: Effect of Aβ Oligomers at Central Synapses
Volume: 5 Issue: 3
Author(s): Waldo Cerpa, Margarita C. Dinamarca and Nibaldo C. Inestrosa
Affiliation:
Keywords: Alzheimer's disease, senile plaque, amyloid β-peptide, neurodegeneration, synaptic toxicity, amyloid oligomers, acetylcholinesterase, Wnt-signaling pathway
Abstract: Alzheimers disease (AD) is the most prevalent neurodegenerative disease in the growing population of elderly people. A characteristic of AD is the accumulation of plaques in the brain of AD patients, and theses plaques mainly consist of aggregates of amyloid β-peptide (Aβ). All converging lines of evidence suggest that progressive accumulation of the Aβ plays a central role in the genesis of Alzheimers disease and it was long understood that Aβ had to be assembled into extracellular amyloid fibrils to exert its cytotoxic effects. This process could be modulated by molecular chaperones which inhibit or accelerate the amyloid formation. The enzyme Acetylcholinesterase (AChE) induces Aβ fibrils formation, forming a stable complex highly neurotoxic. On the other hand, laminin inhibit the Aβ fibrils formation and depolymerizate Aβ fibrils also. Over the past decade, data have emerged from the use of several sources of Aβ (synthetic, cell culture, transgenic mice and human brain) to suggest that intermediate species called Aβ oligomers are also injurious. Accumulating evidence suggests that soluble forms of Aβ are indeed the proximate effectors of synapse loss and neuronal injury. On the other hand, the member of the Wnt signaling pathway, β-catenin was markedly reduced in AD patients carrying autosomal dominant PS-1. Also, neurons incubated with Aβ revealed a significant dose-dependent decrease in the levels of cytosolic β-catenin an effect which was reversed in cells co-incubated with increasing concentrations of lithium, an activator of Wnt signaling pathway. Wnt signaling blocks the behavioural impairments induced by hippocampal injection of Aβ, therefore the activation of Wnt signaling protects agains the Aβ neurotoxicity. Here we review recent progress about Aβ structure and function, from the formation of amyloid fibrils and some molecular chaperones which modulate the amyloidogenesic process to synaptic damage induce by Aβ oligomers.
Export Options
About this article
Cite this article as:
Cerpa Waldo, Dinamarca C. Margarita and Inestrosa C. Nibaldo, Structure-Function Implications in Alzheimers Disease: Effect of Aβ Oligomers at Central Synapses, Current Alzheimer Research 2008; 5 (3) . https://dx.doi.org/10.2174/156720508784533321
DOI https://dx.doi.org/10.2174/156720508784533321 |
Print ISSN 1567-2050 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5828 |
Call for Papers in Thematic Issues
New Advances in the Prevention, Diagnosis, Treatment, and Rehabilitation of Alzheimer's Disease
Aims and Scope: Introduction: Alzheimer's disease (AD) poses a significant global health challenge, with an increasing prevalence that demands concerted efforts to advance our understanding and strategies for prevention, diagnosis, treatment, and rehabilitation. This thematic issue aims to bring together cutting-edge research and innovative approaches from multidisciplinary perspectives to address ...read more
Current updates on the Role of Neuroinflammation in Neurodegenerative Disorders
Neuroinflammation is an invariable hallmark of chronic and acute neurodegenerative disorders and has long been considered a potential drug target for Alzheimer?s disease (AD) and dementia. Significant evidence of inflammatory processes as a feature of AD is provided by the presence of inflammatory markers in plasma, CSF and postmortem brain ...read more
Deep Learning for Advancing Alzheimer's Disease Research
Alzheimer's disease (AD) poses a significant global health challenge, with an increasing number of individuals affected yearly. Deep learning, a subfield of artificial intelligence, has shown immense potential in various domains, including healthcare. This thematic issue of Current Alzheimer Research explores the application of deep learning techniques in advancing our ...read more
Diagnostic and therapeutic biomarkers of dementia
Dementia affects 18 million people worldwide. Dementia is a syndrome of symptoms caused by brain disease, usually chronic or progressive, clinically characterized by multiple impairments of higher cortical functions such as memory, thinking, orientation, and learning. In addition, in the course of dementia, cognitive deficits are observed, which often hinder ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
The Association of Microglial Activation and Amyloid Reduction in APP+PS1 Transgenic Mice
Current Medicinal Chemistry - Immunology, Endocrine & Metabolic Agents Polydeoxyribonucleotide (PDRN): A Safe Approach to Induce Therapeutic Angiogenesis in Peripheral Artery Occlusive Disease and in Diabetic Foot Ulcers
Cardiovascular & Hematological Agents in Medicinal Chemistry Brain Aging in African-Americans: The Atherosclerosis Risk in Communities (ARIC) Experience
Current Alzheimer Research Transgenic Mice as a Model for Alzheimers Disease
Current Alzheimer Research Stroke Subtypes and their Possible Implication in Stroke Prevention Drug Strategies
Current Vascular Pharmacology Cholesterol Oxidation Products and Disease: An Emerging Topic of Interest in Medicinal Chemistry
Current Medicinal Chemistry Chronic Kidney Disease and Sleeping Disordered Breathing (SDB)
Current Hypertension Reviews Group I Metabotropic Receptor Neuroprotection Requires Akt and Its Substrates that Govern FOXO3a, Bim, and β-Catenin During Oxidative Stress
Current Neurovascular Research Primary Progressive Aphasia-Defining Genetic and Pathological Subtypes
Current Alzheimer Research Effect of Withania somnifera Supplementation on Rotenone-Induced Oxidative Damage in Cerebellum and Striatum of the Male Mice Brain
Central Nervous System Agents in Medicinal Chemistry Non-steroidal Anti-inflammatory Drugs and Cyclooxygenase in Alzheimer s Disease
Current Drug Targets Mechanisms of Mononuclear Phagocyte Recruitment in Alzheimers Disease
CNS & Neurological Disorders - Drug Targets Immune-Inflammatory Responses and Oxidative Stress in Alzheimers Disease: Therapeutic Implications
Current Pharmaceutical Design Immunophilins in Nervous System Degeneration and Regeneration
Current Topics in Medicinal Chemistry Chinese Herbs as Immunomodulators and Potential Disease-Modifying Antirheumatic Drugs in Autoimmune Disorders
Current Drug Metabolism Methodologies Related to Computational Models in View of Developing Anti-Alzheimer Drugs: An Overview
Current Drug Discovery Technologies The Role of Intranasal Oxytocin in the Treatment of Patients with Schizophrenia: A Systematic Review
CNS & Neurological Disorders - Drug Targets S-nitrosation/Denitrosation in Cardiovascular Pathologies: Facts and Concepts for the Rational Design of S-nitrosothiols
Current Pharmaceutical Design Brain: The Potential Diagnostic and Therapeutic Target for Glaucoma
CNS & Neurological Disorders - Drug Targets Calmodulin in Complex with Proteins and Small Molecule Ligands: Operating with the Element of Surprise; Implications for Structure-Based Drug Design
Current Computer-Aided Drug Design